Oruka Therapeutics (NASDAQ:ORKA) Coverage Initiated at Leerink Partners

Equities researchers at Leerink Partners started coverage on shares of Oruka Therapeutics (NASDAQ:ORKA) in a report released on Tuesday, MarketBeat.com reports. The brokerage set an “outperform” rating and a $44.00 price target on the stock. Leerink Partners’ price target would suggest a potential upside of 73.36% from the stock’s previous close.

ORKA has been the topic of a number of other reports. TD Cowen began coverage on shares of Oruka Therapeutics in a report on Monday. They set a “buy” rating on the stock. Wedbush began coverage on shares of Oruka Therapeutics in a report on Wednesday, September 4th. They set an “outperform” rating and a $40.00 target price on the stock. Jefferies Financial Group began coverage on shares of Oruka Therapeutics in a report on Friday, September 13th. They set a “buy” rating and a $40.00 target price on the stock. Finally, Lifesci Capital began coverage on shares of Oruka Therapeutics in a report on Monday. They set an “outperform” rating and a $41.00 target price on the stock. Four equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $41.25.

Oruka Therapeutics Price Performance

NASDAQ ORKA opened at $25.38 on Tuesday. Oruka Therapeutics has a 52 week low of $18.72 and a 52 week high of $53.88.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.